



MISSISSIPPI DIVISION OF
MEDICAID

MISSISSIPPI DIVISION OF MEDICAID
Pharmacy & Therapeutics Committee Meeting

Woolfolk Building
Conference Center East, Room 145
Jackson, MS 39201-1399

August 12, 2014
10:00am to 5:00pm

MINUTES

Committee Members Present:

Anne A. Norwood, FNP, PhD
Billy Ray Brown, Pharm.D.
D. Stanley Hartness, M.D.
Deborah Minor, Pharm.D.
Geri Lee Weiland, M.D.
John W. Gaudet, M.D.
Maretta M. Walley, R.Ph., J.D.
Ryan Harper, Pharm.D.
Sharon R. Dickey, Pharm.D.
Wilma Johnson Wilbanks, R.Ph.

Committee Members Not Present:

Carol Tingle, M.D.
Lee Voulters, M.D.

Division of Medicaid Staff Present:

Judith Clark, R.Ph., Pharmacy Director
William Thompson, Pharmacy Deputy Director
Terri Kirby, R.Ph., Pharmacist III
Shannon Hardwick, R.Ph., Pharmacist III
Dell Williams, Operations Management Analyst
Donna Mills, Operations Management Analyst

Contract Staff/GHS Staff Present:

Chad Bissell, Pharm.D., M.B.A.
Jeff Barkin, M.D., DFAPA
Steve Ober, M.D.
Shelagh Harvard

Other Contract Staff Present:

Felicia Lobrano, RN, BSN, Xerox
Lew Anne Snow, RN, BSN, Xerox
Ben Banahan, Ph.D., University of Mississippi
School of Pharmacy

I. Call to Order

Ms. Wilma Wilbanks, Chairperson, called the meeting to order at 10:02 a.m.

II. Introductions

Ms. Judith Clark, the Mississippi Department of Medicaid (DOM) Pharmacy Bureau Director, welcomed the Pharmacy & Therapeutics (P&T) Committee and all guests in the audience.

She recognized four Governor-reappointed Committee members: Dr. Carolyn Tingle, Dr. Anne Norwood, Dr. Deborah Minor, and Dr. Ryan Harper.

She introduced Goold Health Systems, DOM's Preferred Drug List (PDL) and Supplemental Rebate (SR) vendor. All parties seated at the table introduced themselves and gave a brief statement about their professional credentials and affiliations.

Ms. Clark introduced DOM staff members Billy Thompson, Dell Williams, and Donna Mills. Ms. Clark recognized DOM contractors in the audience, including Felicia Lobrano and Lew Anne Snow from Xerox, Dr. Steve Ober from Goold Health Systems, and Dr. Ben Banahan from the University of the Mississippi School of Pharmacy's MS-DUR Program.

III. Administrative Matters

Ms. Clark reviewed Committee policies and procedures.

Ms. Clark reminded guests to sign in via the electronic process available through the DOM website (www.medicaid.ms.gov) prior to the meeting. She stated that copies of the agenda and the public comment guidelines are available at the sign-in table. She stated that there is a separate sign in sheet for advocates and reminded guests that advocate presenters are limited to 3 minutes of general comment about a disease, not specific to a drug. She noted that industry presenters must provide their full name, drug name, identification, and company affiliation when signing in. She stated that industry presenters are allowed 3 minutes per drug and that no handouts are permitted. Presenters are requested to sign in at least 10 minutes prior to start of meeting.

Ms. Clark stated that any documents used in the meeting that are not marked confidential and proprietary will be posted on DOM's website (www.medicaid.ms.gov) after the meeting.

Ms. Clark reviewed policies related to food and drink, cell phones and pagers, discussions in the hallways, and emergency procedures for the building.

Ms. Clark stated that DOM aggressively pursues supplemental rebates. Mississippi is part of the Sovereign States Drug Consortium (SSDC) pool.

Ms. Clark reviewed the voting procedure and reminded the Committee that, in accordance with the Mississippi Open Meetings Act, the minutes reflect each person's vote. She requested that the Chair announce the recommendation, motions, and the names of committee members

making motions. The minutes for each P&T Committee meeting are posted to the DOM website (www.medicaid.ms.gov) within 30 days of the meeting. The meeting minutes will be posted no later than October 1, 2014. Decisions will be announced no later than September 1, 2014 on the DOM website.

Ms. Clark stated that the P&T Committee works in an advisory capacity and that DOM is responsible for final decisions related to the PDL. She reviewed the meeting process. She stated that DOM takes into account recommendations from both the P&T Committee and the clinical contractor before making a final decision. She stated that the PDL is completely updated once per year; quarterly updates are implemented throughout the year.

Ms. Clark requested that Committee members complete their travel vouchers and reviewed the contents of the folders provided to each Committee member.

IV. Division of Medicaid Update

No further update was provided.

V. Approval of May 13, 2014 Meeting Minutes

Ms. Wilbanks asked for additions or corrections to the minutes from the May 13, 2014 meeting. Dr. Weiland moved to accept the minutes as presented. Dr. Hartness seconded. Votes were taken, and the motion was adopted.

VI. PDL Compliance/Generic Percent Report Updates

Dr. Barkin provided an explanation of the PDL Compliance and Generic Percent reports.

- A.** Dr. Barkin reviewed the PDL Compliance Report; overall compliance for Q2 2014 was 96.5%.
- B.** Dr. Barkin reviewed the Generic Percent Report; overall generic utilization for Q2 2014 was 78.4%.

VII. Drug Class Announcements

Dr. Bissell introduced three new classes: Antiretrovirals, Movement Disorder Agents, and Smoking Deterrent Agents. He noted that the Macrolides/Ketolides category has been expanded and renamed Antibiotics, Miscellaneous. He discussed the philosophy behind the antiretroviral category recommendations.

VIII. First Round of Extractions

All categories were recommended for extraction.

IX. Public Comments

Ms. Clark reviewed the public comment process.

Anika Bridgewater, ViiV Healthcare, yielded her time back to the Epzicom.

Anika Bridgewater, ViiV Healthcare, spoke in favor of Selzentry.

Christy Copeland, Salix Pharmaceuticals, spoke in favor of Fulyzaq.

Aida Moro, Lundbeck, spoke in favor of Xenazine. A robust clinical discussion followed.

Michele Puyear, Gilead, spoke in favor of Stribild. A robust clinical discussion followed.

Ed Rutledge, Celgene, spoke in favor of Otezla. A robust clinical discussion followed.

Ashlie Singletary, Merck, spoke in favor of Zontivity. A robust clinical discussion followed.

X. Second Round of Extractions

All categories were recommended for extraction.

XI. Non-Extracted Categories

All classes were recommended for extraction.

XII. Extracted Therapeutic Class Reviews

A. Antiretrovirals

GHS recommended that the following list be approved. Dr. Brown moved to amend the recommendation to move Stribild, nevirapine, Trizivir, Viracept, and generic Combivir to preferred and move Fuzeon to non-preferred, all with grandfathering. Dr. Norwood seconded. A robust clinical discussion followed. Votes were taken, and the motion was not adopted. Dr. Brown, Dr. Norwood, and Dr. Dickey voted in favor of the motion; Dr. Hartness, Dr. Minor, Dr. Weiland, Dr. Gaudet, Ms. Walley, Dr. Harper, and Ms. Wilbanks voted against the motion. Dr. Minor motioned to accept Goold's recommendations with the exception that nevirapine, Trizivir, Viracept and generic Combivir remain preferred and move Fuzeon to non-preferred with grandfathering. This recommendation includes accepting the original recommendation of moving Stribild to non-preferred with grandfathering. Dr. Hartness seconded. The Committee recommended that the Drug Utilization Review board track and report on medication possession ratios of patients using combination therapy vs. single tablet regimens. . Votes were taken, and the motion was adopted. The approved category is below.

MS DOM will provide weekly pill planners to this population.

PREFERRED AGENTS

NON-PREFERRED AGENTS

PREFERRED AGENTS	NON-PREFERRED AGENTS
INTEGRASE STRAND TRANSFER INHIBITORS	
ISENTRESS (raltegravir potassium) TIVICAY (dolutegravir sodium)	
NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTI)	
abacavir sulfate didanosine DR capsule EMTRIVA (emtricitabine) EPIVIR (lamivudine) lamivudine stavudine VIDEX SOLUTION (didanosine) VIREAD (tenofovir disoproxil fumarate) ZIAGEN (abacavir sulfate) zidovudine	RETROVIR (zidovudine)** VIDEX EC (didanosine) ** ZERIT (stavudine) **
NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI)	
EDURANT (rilpivirine) nevirapine SUSTIVA (efavirenz)	INTELENCE (etravirine) ** RESCRIPTOR (delavirdine mesylate) ** VIRAMUNE (nevirapine) ** VIRAMUNE ER (nevirapine) **
PROTEASE INHIBITORS (PEPTIDIC)	
NORVIR (ritonavir) REYATAZ (atazanavir) VIRACEPT (nelfinavir mesylate)	CRIXIVAN (indinavir) ** LEXIVA (fosamprenavir) ** INVIRASE (saquinavir mesylate) **
PROTEASE INHIBITORS (NON-PEPTIDIC)	
PREZISTA (darunavir ethanolate)	APTIVUS (tipranavir) *
ENTRY INHIBITORS – CCR5 CO-RECEPTOR ANTAGONISTS	
	SELZENTRY (maraviroc) **
ENTRY INHIBITORS – FUSION INHIBITORS	
	FUZEON (enfuvirtide)**
COMBINATION PRODUCTS - NRTIs	
EPZICOM (abacavir/lamivudine) lamivudine/zidovudine TRIZIVIR (abacavir/lamivudine/zidovudine)	abacavir/lamivudine/zidovudine** COMBIVIR (lamivudine/zidovudine) **
COMBINATION PRODUCTS – NUCLEOSIDE & NUCLEOTIDE ANALOG RTIs	
TRUVADA (emtricitabine/tenofovir)	
COMBINATION PRODUCTS – NUCLEOSIDE & NUCLEOTIDE ANALOGS & INTEGRASE INHIBITORS	
	STRIBILD (elvitegravir/cobicistat/emtricitabine/tenofovir) **
COMBINATION PRODUCTS – NUCLEOSIDE & NUCLEOTIDE ANALOGS & NON-NUCLEOSIDE RTIs	
ATRIPLA (efavirenz/emtricitabine/tenofovir) COMPLERA (emtricitabine/rilpivirine/tenofovir)	
COMBINATION PRODUCTS – PROTEASE INHIBITORS	
KALETRA (lopinavir/ritonavir)	

B. Movement Disorder Agents

GHS recommended that the following list be approved. A robust clinical discussion followed. Dr. Weiland moved to accept the recommendation. Dr. Harper seconded. Votes were taken, and the motion was adopted. The approved category is below.

PREFERRED AGENTS	NON-PREFERRED AGENTS
	XENAZINE (tetrabenazine)**

C. Smoking Deterrents

GHS recommended that the following list be approved. A robust clinical discussion followed. Dr. Hartness moved to accept the recommendation. Dr. Dickey seconded. Votes were taken, and the motion was adopted. Dr. Minor motioned that the Smoking Deterrent class be excluded from the monthly prescription limit. Dr. Dickey seconded. Votes were taken, and the motion was adopted. The approved category is below.

PREFERRED AGENTS	NON-PREFERRED AGENTS
NICOTINE TYPE	
nicotine gum nicotine lozenge nicotine patch	NICODERM CQ PATCH NICORETTE LOZENGE NICORETTE GUM NICOTROL INHALER NICOTROL NASAL SPRAY
NON-NICOTINE TYPE	
bupropion ER CHANTIX (varenicline)	ZYBAN (bupropion)

D. Antibiotics, Miscellaneous

GHS recommended that the following list be approved. A robust clinical discussion followed. Dr. Harper moved to accept the recommendation. Dr. Weiland seconded. Votes were taken, and the motion was adopted. The approved category is below.

PREFERRED AGENTS	NON-PREFERRED AGENTS
KETOLIDES	
	KETEK (telithromycin)
LINCOSAMIDE ANTIBIOTICS	
CLEOCIN SOLUTION (clindamycin) clindamycin capsules	CLEOCIN (clindamycin) CLEOCIN PEDIATRIC (clindamycin) clindamycin pediatric solution clindamycin solution
MACROLIDES	
azithromycin clarithromycin ER clarithromycin IR E.E.S. Suspension 200 (erythromycin ethylsuccinate) ERY-TAB (erythromycin)	BIAXIN (clarithromycin) BIAXIN XL (clarithromycin) E.E.S. (ethylsuccinate) E.E.S. Suspension 400 (erythromycin ethylsuccinate) E-MYCIN (erythromycin) ERYC (erythromycin) ERYPED Suspension (erythromycin ethylsuccinate) ERYTHROCIN (erythromycin stearate) erythromycin erythromycin estolate PCE (erythromycin) ZITHROMAX (azithromycin) ZMAX (azithromycin)
NITROFURAN DERIVATIVES	
nitrofurantoin nitrofurantoin monohydrate macrocrystals	FURADANTIN (nitrofurantoin) MACROBID (nitrofurantoin monohydrate macrocrystals) MACRODANTIN (nitrofurantoin)

E. Analgesics, Narcotic – Long-Acting

GHS recommended that the following list be approved. A robust clinical discussion followed. Dr. Weiland moved to accept the recommendation. Dr. Norwood seconded. Votes were taken, and the motion was adopted. The approved category is below.

PREFERRED AGENTS	NON-PREFERRED AGENTS
fentanyl patches methadone morphine ER tablets OPANA ER (oxymorphone)	AVINZA (morphine) BUTRANS (buprenorphine) CONZIP ER (tramadol) DOLOPHINE (methadone) DURAGESIC (fentanyl) EMBEDA (morphine/naltrexone) EXALGO (hydromorphone) hydromorphone ER KADIAN (morphine) MS CONTIN (morphine) morphine ER capsules NUCYNTA ER (tapentadol) oxycodone ER OXYCONTIN (oxycodone) oxymorphone ER RYZOLT (tramadol) tramadol ER ULTRAM ER (tramadol) XARTEMIS XR (oxycodone/APAP) ZOHYDRO ER (hydrocodone bitartrate)

F. Pulmonary Arterial Hypertension

GHS recommended that the following list be approved. A robust clinical discussion followed. Dr. Hartness moved to accept the recommendation. Dr. Weiland seconded. Votes were taken, and the motion was adopted. The approved category is below.

PREFERRED AGENTS	NON-PREFERRED AGENTS
	TYVASO (treprostinil) ORENITRAM ER (treprostinil) VENTAVIS (iloprost)

XIII. New Drug/New Generic Reviews

A. Luzu

GHS recommended that Luzu be made a non-preferred drug in the Antifungals (Topical) category. A robust clinical discussion followed. Dr. Dickey moved to accept the recommendation. Dr. Weiland seconded. Votes were taken, and the motion was adopted. The approved category is below.

PREFERRED AGENTS	NON-PREFERRED AGENTS
ANTIFUNGALS	
ciclopirox cream/gel/suspension clotrimazole econazole ketoconazole cream ketoconazole shampoo miconazole OTC nystatin terbinafine OTC cream,gel,spray tolnaftate OTC	BENSAL HP (benzoic acid/salicylic acid) CICLODAN KIT ciclopirox kit/shampoo/solution CNL 8 (ciclopirox) ERTACZO (sertaconazole) EXELDERM (sulconazole) EXTINA (ketoconazole) JUBLIA (efinaconazole)^{NR} ketoconazole foam LAMISIL (terbinafine) solution LOPROX (ciclopirox) LUZU (luliconazole) MENTAX (butenafine) NAFTIN (naftifine) NIZORAL (ketoconazole) OXISTAT (oxiconazole) PEDIADERM AF (nystatin) PENLAC (ciclopirox) VUSION (miconazole/petrolatum/zinc oxide)
ANTIFUNGAL/STEROID COMBINATIONS	
clotrimazole/betamethasone cream nystatin/triamcinolone	clotrimazole/betamethasone lotion LOTRISONE (clotrimazole/betamethasone)

B. Zykadia

GHS recommended that Zykadia be made a preferred drug in the Antineoplastics – Selected Systemic Enzyme Inhibitors category. A robust clinical discussion followed. Dr. Weiland moved to accept the recommendation. Dr. Hartness seconded. Votes were taken, and the motion was adopted. The approved category is below.

PREFERRED AGENTS	NON-PREFERRED AGENTS
BOSULIF (bosutinib) CAPRELSA (vandetanib) COMETRIQ (cabozantinib) GILOTRIF (afatinib) GLEEVEC (imatinib mesylate) ICLUSIG (ponatinib) IMBRUVICA (ibrutinib) INLYTA (axitinib) IRESSA (gefitinib) JAKAFI (ruxolitinib) MEKINIST (trametinib dimethyl sulfoxide) NEXAVAR (sorafenib)	

PREFERRED AGENTS	NON-PREFERRED AGENTS
SPRYCEL (dasatinib) STIVARGA (regorafenib) SUTENT (sunitinib) TAFINLAR (dabrafenib) TARCEVA (erlotinib) TASIGNA (nilotinib) TYKERB (lapatinib ditosylate) vandetanib VOTRIENT (pazopanib) XALKORI (crizotinib) ZELBORAF (vemurafenib) ZYKADIA (ceritinib)	

C. Sitavig

GHS recommended that Sitavig be made a non-preferred drug in the Antivirals (Oral) – Antihyperthermic Agents category. A robust clinical discussion followed. Dr. Gaudet moved to accept the recommendation. Dr. Dickey seconded. Votes were taken, and the motion was adopted.

PREFERRED AGENTS	NON-PREFERRED AGENTS
acyclovir valacyclovir	famciclovir FAMVIR (famciclovir) SITAVIG (acyclovir) VALTREX (valacyclovir) ZOVIRAX (acyclovir)

D. Otezla

GHS recommended that Otezla be made a non-preferred drug in the Cytokine & CAM Antagonists category. Dr. Minor moved to accept the recommendation. Dr. Dickey seconded. Votes were taken, and the motion was adopted. The approved category is below.

PREFERRED AGENTS	NON-PREFERRED AGENTS
ENBREL (etanercept) HUMIRA (adalimumab) methotrexate SIMPONI (golimumab)	ACTEMRA (tocilizumab) ^{NR} CIMZIA (certolizumab) ILARIS (canakinumab) KINERET (anakinra) ORENCIA (abatacept) OTEZLA (apremilast) OTREXUP (methotrexate) REMICADE (infliximab) RHEUMATREX (methotrexate) STELARA (ustekinumab) TREXALL (methotrexate) XELJANZ (tofacitinib)

E. Zontivity

GHS recommended that Zontivity be made a non-preferred drug in the Platelet Aggregation Inhibitors category. Dr. Hartness moved to accept the recommendation. Dr. Harper seconded. Votes were taken, and the motion was adopted. The approved category is below.

PREFERRED AGENTS	NON-PREFERRED AGENTS
AGGRENOX (dipyridamole/aspirin) cilostazol clopidogrel dipyridamole	BRILINTA (ticagrelor) EFFIENT (prasugrel) PERSANTINE (dipyridamole) PLAVIX (clopidogrel) PLETAL (cilostazol) ticlopidine ZONTIVITY (vorapaxar)

F. Hetlioz

GHS recommended that Hetlioz be made a non-preferred drug in the Sedative Hypnotics, Others category. Dr. Weiland moved to accept the recommendation. Dr. Brown seconded. Votes were taken, and the motion was adopted. The approved category is below.

PREFERRED AGENTS	NON-PREFERRED AGENTS
BENZODIAZEPINES	
estazolam flurazepam temazepam (15mg and 30mg) triazolam	DALMANE (flurazepam) DORAL (quazepam) HALCION (triazolam) RESTORIL (temazepam) temazepam (7.5mg and 22.5mg) SmartPA
OTHERS	
zaleplon zolpidem	AMBIEN (zolpidem) AMBIEN CR (zolpidem) EDLUAR (zolpidem) HETLIOZ (tasimelteon) INTERMEZZO (zolpidem) LUNESTA (eszopiclone) ROZEREM (ramelteon) SILENOR (doxepin) SONATA (zaleplon) zolpidem ER ZOLPIMIST (zolpidem)

XIV. Other Business

The next DUR Board meeting will take place on August 21, 2014. Dr. Null has moved on to another position; Dr. Banahan is filling in during the interim.

The uniform PDL is currently scheduled to deploy on October 1, 2014.

Ms. Clark called for nominations for Chairperson and Vice-Chairperson. Dr. Norwood nominated Dr. Walley for Chairperson. Dr. Weiland nominated Ms. Wilbanks for Chairperson. Dr. Norwood withdrew her nomination of Dr. Walley. Votes were taken, and the motion was

adopted. Dr. Weiland nominated Dr. Harper for Vice-Chairperson. Dr. Norwood seconded. Votes were taken, and the motion was adopted.

Dr. Hartness noted that Mississippi placed second in the national 2014 Tar Wars Student Poster Contest (<http://www.aafp.org/patient-care/public-health/tobacco-cessation/tar-wars/winners.html>).

XV. Next Meeting Date

The next meeting of the Pharmacy & Therapeutics Committee will be held on October 21, 2014 at 10:00 a.m. in the Woolfolk Building, Conference Center East, Room 145, in Jackson, Mississippi.

XVI. Adjournment

The meeting adjourned at 12:20 p.m.